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Abstract 
UHMK1 (also known as KIS) is a serine/threonine 
kinase initially identified as a Stathmin interacting 
protein. UHMK1 is characterized by an N-terminal 
kinase domain and a C-terminal UHM motif. 
Through the UHM motif, the protein is capable of 
interacting with splicing factors, such as SF1 and 
SF3B1, involved in early steps of spliceosome 
assembly.  UHMK1 is ubiquitously but 
preferentially expressed in the developing nervous 
system, where it plays a role in mRNA processing, 
translational enhancing, neurite outgrowth and 
postsynaptic plasticity. Protein interactions between 
UHMK1 and a range of proteins pointed to its 
function in different cellular processes, such as RNA 
metabolism, cell cycle progression, cell migration 
and membrane trafficking. More recently, a role of 
UHMK1 in cell differentiation has also been 
proposed. 
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Identity 
Other names 
KIS, KIST, P-CIP2 
HGNC (Hugo) 
UHMK1 
Location 
1q23.3 
Location (base pair) 
Starts at 162497174 and ends at 162529629 bp from 
pter (according to GRCh38.p7, 2016) 
DNA/RNA 
Description 
The UHMK1 gene is located on the chromosome 1, 
band q23, orientated in the plus (+) strand. The 
genomic locus spans 32456 base pairs 
(NC_000001.11), contains 8 exons and two 
alternative first exons. 
Transcription 
Three alternatively spliced transcripts of 8535, 8194 
and 8446 base pairs are formed (NM_175866, 
NM_001184763 and NM_144624, respectively). 
The transcript variant 1 (NM_175866) codes for the 
longest protein isoform, which has 419 amino acids 
in length (isoform 1; NP_787062). The transcript 
variant 2 (NM_001184763) differs in the 5' UTR and 
initiates translation at the alternative start codon. The 
resulting protein (isoform 2; NP_0011716921) of 
345 amino acids has a distinct 15 amino acids N-
terminal, encoded by the alternative exon 1, and the 
remaining 330 amino acids encoded by exons 2-8. 
The transcript variant 3 (NM_144624) lacks exon 7, 
which results in a frame shift and early stop codon 
within exon 8. The encoded protein (isoform 3; 
NP_653225) of 344 residues, shares the first 341 
amino acids (exons 1-6) with isoform 1, differing 
only in the last 3 amino acids at the C-terminal 
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(Figure 1). An additional processed transcript of 
3345 bp (ENST00000282169.8) retaining intron 2 
(between exons 2 and 3), which does not contain an 
open reading frame (ORF) has been annotated for 
this gene. Moreover, the first 540 nucleotides of 
UHMK1 locus (NC_000001.11) are shared with the 
LOC105371497 gene, which produces a 708 bp long 
non-coding RNA (XR_922225.1), transcribed in the 
opposite direction of UHMK1 
(https://www.ncbi.nlm.nih.gov/gene/127933). 
 
 
Figure 1. Genomic organization, alternative splicing and protein isoforms of UHMK1.  Exons are 
represented by numbered blue boxes and introns by the black line. The positions of the exons within the genome 
(NC_000001.11) are numbered. Exon joining is represented for each transcript by light green, purple and orange 
continuous lines; dashed lines indicate the respective protein isoform; dotted lines indicate the alternatively first 
exon usage. Size of the transcript variants are shown in parentheses. The transcript variant 1 codes for the longer 
protein (UHMK1 isoform 1, light green). The transcript variant 2 comprises an alternative first exon (light purple 
box), which encodes the distinct 15 amino acids N-terminal of the protein (UHMK1 isoform 2, purple). The 
transcript variant 3 lacks exon 7, whose excision results in a frameshift and early stop codon in exon 8. The 
resulting UHMK1 isoform 3 (orange), exhibits a distinct C-terminal formed by 3 aminoacids encoded by the 
beginning of exon 8. Sizes were scaled up, where 0.5 cm symbolizes 150 bp of exonic region (blue boxes) and 
624 bp of intronic regions (black line). Number and position of aminoacids are depicted for each isoform. 
 
Protein 
 
Figure 2. Diagram representing UHMK1 protein and the posttranslational modifications.  UHMK1 is 
characterized by an N-terminal kinase core of 282 aminoacids, represented in green and a C-terminal UHM of 
100 aminoacids, represented in violet. All residues described to be phosphorylated or ubiquitinated in large scale 
proteomic studies are depicted. Source: Phosphoproteomic databases PhosphoSitePlus 
(http://www.phosphosite.org) UHM: U2AF homology motif (modified from Archangelo, et al. 2013).
 
Description 
UHMK1 is a serine/threonine kinase with calculated 
molecular weight of 46.5 kDa and a theoretical pI of 
5.59 (PhosphoSite Plus). The primary sequence of 
the protein is characterized by an N-terminal kinase 
core (282 aminoacids) and the C-terminal U2AF 
homology motif (UHM), responsible for establishing 
protein interactions with UHM-ligand motifs 
(ULM), particularly present among splicing factors 
(Kielkopf et al., 2004; Manceau et al., 2006). 
UHMK1 phosphorylates preferentially proline 
directed serine residues on its target proteins 
(Maucuer et al., 2000). The lysine 54 within the N-
terminal region is essential for its kinase activity and 
autophosphorylation activity has been observed 
(Boehm et al., 2002; Maucuer et al., 1997). A variety 
of large scale proteomic studies identified two types 
of posttranslational modifications within UHMK1, 
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namely lysine-ubiquitination (K190-ub, K282-ub, 
K383-ub and K387-ub) and phosphorylation (Y197-
p, S283-p and S290-p) as indicated at the 
phosphoproteomic database PhosphoSitePlus 
(http://www.phosphosite.org) (Figure 2). 
Expression 
UHMK1 is ubiquitously expressed throughout rat 
and human tissues, with enriched expression in the 
nervous system (Bieche et al., 2003; Caldwell et al., 
1999; Maucuer et al., 1997). Uhmk1 mRNA is 
expressed during rat embryonic development and 
increases after birth and during the first month of 
brain development (Bieche et al., 2003). In the adult 
brain, in situ hybridization revealed remarkable 
expression in the substantia nigra and some sensorial 
and motor nuclei in the brain stem (Bieche et al., 
2003). In the human brain, UHMK1 expression was 
detected in all regions examined, with highest levels 
in the deeper cortical layers. Strong expression was 
observed in dentate gyrus, CA1, CA3 and CA4 
regions of the hippocampus, in Purkinje cells and 
granule cell layer of the cerebellum. No expression 
was detected in the white matter (Bristow et al., 
2009). 
In the hematopoietic compartment, high levels of 
UHMK1 transcripts were observed in differentiated 
lymphocytes (CD4+, CD8+ and CD19+) compared 
to the progenitor enriched subpopulation (CD34+) or 
leukemia cell lines. UHMK1 expression was 
upregulated in megakaryocytic-, monocytic- and 
granulocytic-induced differentiation of leukemia cell 
lines and in erythrocytic-induced differentiation of 
primary CD34+ cells (Barbutti et al., 2017). 
Levels of UHMK1 protein are induced by mitogens. 
In serum starved cells, UHMK1 expression was 
reduced in contrast to serum stimulated cells (Boehm 
et al., 2002; Crook et al., 2008; Petrovic et al., 2008). 
UHMK1 expression increased after quiescent 
peripheral blood lymphocytes (PBLs) were induced 
to proliferate upon mitogen activation (Barbutti et 
al., 2017). Moreover, the amount of UHMK1 protein 
varies throughout the cell cycle. In synchronized 
cells, UHMK1 accumulates in G1 phase and 
decreases during S phase of the cell cycle 
(Archangelo et al., 2013). 
Little is known about the transcriptional regulation 
of UHMK1, which was described as direct target of 
the transcription factors GABP (Crook et al., 2008) 
and FOXM1 (Petrovic et al., 2008). The core 
promoter region of UHMK1 was described within -
141 to -41 base pairs upstream of the transcription 
start site and has no consensus sequences for TATA 
or CCAAT boxes. Instead, it has GC-box and 3 Ets-
binding sites (EBS-1, EBS-2 and EBS-3), which are 
essential for the promoter activity, in vitro. The 
regions spanning EBS-1 and EBS-2 (-103/-73 bp), 
and EBS-3 (-52/-42 bp) bind GABP in response to 
serum, leading to UHMK1 expression, cell 
migration and cell cycle progression of VSCM cells 
(Crook et al., 2008). 
FoxM1 binds an internal regulatory region within 
UHMK1 and transactivates its expression in vitro. 
FoxM1 appears to be essential for serum-dependent 
activation of UHMK1 mRNA expression, as 
assessed in FoxM1-/- MEF cells. It was suggested 
that FoxM1-induced UHMK1 expression is required 
for UHMK1-mediated phosphorylation and 
consequently degradation of CDKN1B (p27Kip1) 
(Petrovic et al., 2008). 
Furthermore, UHMK1 was described as 
transcriptional target of the WD repeat domain 5 
(WDR5), a core component of the KMT2A (MLL) / 
SETD1A complex, known for its methyltransferase 
activity on H3 lysine 4 (H3K4). The H3K4me3 
epigenetic modification correlates with gene 
activation, thus it is suggested that WDR5-mediated 
H3K4me3 at UHMK1 locus promotes its expression 
(Chen et al., 2015). 
 
Figure 3. Subcellular localization of Uhmk1. Confocal image of HeLa cells transiently transfected with 
plasmid expressing ha-tagged Uhmk1 (pECE-HA-Kis; Manceau et al, 2008). Ectopic Uhmk1 localizes mainly to 
the nucleus and to a lesser extent to the cytoplasm. The anti-Kis 3B12 antibody (Manceau et al, 2012) and 
Phalloidin (Invitrogen A1238) were used to detected Uhmk1 and Actin, respectively. 63x objective, zoom 2,5 x. 
Personal data. 
 
Localisation 
The UHMK1 protein localizes mainly to the nucleus 
and to a lesser extent to the cytoplasm (Boehm et al., 
2002; Maucuer et al., 1997) (Figure 3). Shuttling 
between nucleus and cytoplasm has been described 
for the GFP-fused protein by fluorescence recovery 
after photobleaching (FRAP) (Francone et al., 2010). 
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The kinase domain is essential for the protein nuclear 
localization, since deletion mutants of this domain, 
particularly the residues 1-211, extinguished Uhmk1 
signal in immunofluorescence analysis (Manceau et 
al., 2008). Overexpressed ha-tagged Uhmk1 
localized to the RNA granules of axon and dendrites 
of cortical neurons (Cambray et al., 2009). Also, a 
nucleolar enriched localization was observed when 
ha-tagged Uhmk1 was co-expressed with its GFP-
fused interacting partner PIMREG (Archangelo et 
al., 2013). 
 
Figure 4. Potential functions of UHMK1. 1- UHMK1 interacts with and phosphorylates the splicing factors 
SF1 and SF3B1. 2- UHMK1 counteracts the inhibitory effect of p27Kip1 on cell cycle. Upon mitogenic activation, 
UHMK1 is upregulated and phosphorylates p27Kip1, which is exported from the nucleus and targeted for 
degradation by the proteasome. 3- UHMK1 impairs cell migration through negatively regulating the microtubule 
destabilizing protein Stathmin (STMN). UHMK1-mediated phosphorylation of STMN on S38 targets the protein 
for degradation. 4- UHMK1 regulates the secretory pathway in neurons and endocrine cells through its 
interaction with the peptidylglycine α-amidating mono-oxigenase (PAM). 5- UHMK1 interacts with components 
of neuronal RNA granules, such as KIF3A, NonO and eEF1A. It also associates with RNP-transported mRNAs 
and stimulates translation driven by the β-actin 3' UTR. 6- UHMK1 interacts with and phosphorylates the 
proliferation marker PIMREG, suggesting a potential role in regulating proliferation. Black arrow: represents the 
mitogen-dependent activation of UHMK1. Grey arrows: indicate the UHMK1-mediated phosphorylation of 
target proteins. Grey dotted arrows: represent the fate of the UHMK1 phosphorylated proteins targeted for 
degradation. P: phosphorylation; Ub: ubiquitination. Illustration was drawn using Servier Medical Art. 
 
Function 
UHMK1 was described to interact with a range of 
proteins, shedding light on different functions of this 
protein in diverse cellular processes (Figure 4). 
UHMK1 is the only kinase that possesses the N-
terminal kinase core juxtaposed to a C-terminal 
U2AF homology motif (UHM) (Maucuer et al., 
1997). Through the UHM motif, UHMK1 interacts 
with the splicing factors SF1 and SF3B1 (Manceau 
et al., 2008). Upon interaction, UHMK1 
phosphorylates SF1, which enhances SF1 specific 
binding to U2AF65 and reduces the SF1-U2AF65 
binding to the 3' splice site RNA (Chatrikhi et al., 
2016; Manceau et al., 2006). In addition, UHMK1 
expression is necessary for normal phosphorylation 
of SF1 in vivo (Manceau et al., 2012). The fact that 
UHMK1 interacts with and regulates splicing factors 
suggests that UHMK1 might be involved in RNA 
metabolism. 
Since UHMK1 is highly expressed in neurons, it is 
expected to exerts important functions in the nervous 
system. It was demonstrated an abnormal 
phosphorylation of SF1 in brain extracts of neonate 
Uhmk1-/- mice. Also, Uhmk1 deletion resulted in 
increased ratio of pre-mRNA relative to mRNA, and 
consequently down-regulation of brain specific 
genes, like cys-loop ligand-gated ion channels and 
metabolic enzymes. Although adult Uhmk1-/- mice 
did not present an obvious phenotype, animal 
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behavior was affected. The Uhmk1-/- mice displayed 
locomotor hyperactivity, reduced fear conditioning 
and learning capacities from aversive stimuli 
(Manceau et al., 2012). 
The murine Uhmk1 was described to interact with 
known components of neuronal RNA granules, such 
as KIF3A, NONO and EEF1A1. The protein 
colocalizes with KIF3A kinesin in neurites and is 
required for neuritic outgrowth in cortical mouse 
neurons. Furthermore, Uhmk1 associates with RNP-
transported mRNAs and stimulate translation driven 
by the β-actin 3' UTR, suggesting that Uhmk1 
contributes to modulate translation in RNA-
transporting granules as a result of local signals 
(Cambray et al., 2009). Still, comparison of primary 
cultures derived from Uhmk1-/- mice did not reveal a 
significant difference in neuritic arborization of 
cortical neurons (Manceau et al., 2012). 
Furthermore, a study investigating Uhmk1 action on 
hippocampal synaptic plasticity in mice, showed that 
Uhmk1 knockdown impaired spine development, 
altered actin dynamics, and reduced postsynaptic 
responsiveness. Moreover, Uhmk1 depletion 
resulted in decrease of the postsynaptic scaffolding 
protein PSD-95 and of AMPA receptor subunits. 
Thus Uhmk1 enhances translation of AMPA 
receptors and stimulates dendritic spine remodeling 
(Pedraza et al., 2014). 
Another described function of UHMK1 involves the 
regulation of secretory pathway in neurons and 
endocrine cells through its interaction with 
peptidylglycine α-amidating mono-oxigenase 
(PAM) (Alam et al., 1996). PAM cytosolic domain 
(CD) phosphorylation by UHMK1 (Ser-949) is 
required for the correct routing of this protein and 
consequently for its ability to affect trafficking in the 
regulated secretion pathway (Alam et al., 2001; 
Caldwell et al., 1999). Lately, it was described an 
intramembrane proteolysis pathway for PAM, 
generating a soluble fragment of the cytosolic 
domain (sf-CD), which accumulates in the nucleus 
in a phosphorylation-dependent manner, modulating 
the expression of genes involved in the secretory 
pathway. UHMK1 phosphorylates sf-CD, 
diminishing its localization in the nucleus and 
negatively regulating the expression of a subset of 
genes (Francone et al., 2010; Rajagopal et al., 2010). 
An extensively documented function of UHMK1 is 
its ability to positively regulate cell cycle 
progression through phosphorylation and inhibition 
of the cyclin dependent kinase inhibitor (CDKI) 
p27Kip1. Upon mitogenic activation, UHMK1 
expression is upregulated and phosphorylates p27Kip1 
on serine 10 (Ser10). As a consequence, p27Kip1 is 
exported from nucleus to cytoplasm, where it is 
targeted to the proteasome and degraded, and has no 
longer inhibitory effect on cell cycle. Thus, UHMK1 
promotes cell cycle re-entry by inactivating p27Kip1 
following growth factor stimulation (Boehm et al., 
2002). 
Another important target of UHMK1 is the 
microtubule-destabilizing protein, Stathmin 
(Maucuer et al., 1995). UHMK1 interacts with and 
phosphorylates Stathmin on serine 38 (Ser38), 
targeting this protein to proteasome. Through 
negative regulation of Stathmin, UHMK1 alter 
microtubule dynamics and consequently impairs cell 
migration (Langenickel et al., 2008). 
UHMK1 expression is upregulated upon 
hematopoietic cell differentiation, thus a possible 
role of UHMK1 in cell differentiation was proposed 
(Barbutti et al., 2017). This idea was supported by 
the fact that UHMK1 mRNA is highly expressed in 
the mature brain and in terminally differentiated 
neural cells (Bieche et al., 2003) as well as during 
osteoclasts differentiation (Choi et al., 2016). The 
human UHMK1 shares high homology with a 
number of species as depicted in Table 1. 
PIMREG (previously known as FAM64A; CATS) is 
a proliferation marker shown to interact with 
UHMK1. The fact that UHMK1 interacts with and 
phosphorylates PIMREG suggests that UHMK1 
regulates PIMREG function and/or localization. 
Nevertheless, the functional implication of this 
interaction remains elusive (Archangelo et al., 
2013). 
Homology 
The human UHMK1 shares high homology with a 
number of species as depicted in Table 1. The human 
UHMK1 shares high homology with a number of 
species as depicted in Table 1. 
Table 1. Homology between the human UHMK1 and other species
Homo sapiens UHMK1 Symbol Protein (% Identity) DNA(% Identity) 
vs. P. troglodytes 
vs. M. mulatta 
UHMK1 
UHMK1 
99.8 (XP_001174268)  
99.8 (NP_001253697) 
99.7 (XM_001174268) 
99.0 (NM_001266768) 
vs. C. lupus UHMK1 99.8 (XP_536143) 95.8 (XM_536143) 
vs. B. taurus UHMK1 99.8 (NP_001192514) 95.9 (NM_001205585) 
UHMK1 (U2AF homology motif kinase 1)  
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vs. M. musculus Uhmk1 99.3 (NP_034763) 93.0 (NM_010633) 
vs. R. norvegicus Uhmk1 99.3 (NP_058989) 92.6 (NM_017293) 
vs. G. gallus UHMK1 88.2 (XP_015145890) 81.6 (XM_015290404) 
vs. D. rerio uhmk1 73.6 (NP_001070127) 69.4 (NM_001076659) 
(Source: http://www.ncbi.nlm.nih.gov/homologene/) 
Mutations 
Somatic 
Recurrent mutations have not been identified for the 
UHMK1 gene. Nonetheless, more than 160 unique 
mutations were reported in this gene in the catalogue 
of somatic mutations in cancer database (COSMIC), 
mainly in lung, gastric, esophageal, colon, rectal and 
hepatocellular/liver cancer 
(http://cancer.sanger.ac.uk/cancergenome/projects/c
osmic). 
Implicated in 
Breast cancer 
Erlotinib resistence in breast cancer treatment was 
attributed to p27Kip1 cytoplasmic localization. 
UHMK1 depletion by siRNA enhanced erlotinib 
cytotoxicity in EGFR-expressing breast cancer cells, 
due to its accumulation in the nucleus and reduced 
p27Kip1 cytoplasmic localization (Zhang et al., 2010). 
Besides, UHMK1 expression was reported to be 
inhibited in a dose-dependent manner by the anti-
HER2 antibody trastuzumab, used for treatment of 
human metastatic breast cancer with HER2 
overexpression (Le et al., 2005). 
Neurological tumors 
Higher levels of UHMK1 transcripts were observed 
in small cohort of neurological tumors associated 
with neurofibromatosis type 1 (NF1). Among the 
NF1-associated tumors analyzed, plexiform 
neurofibroma and malignant peripheral nerve sheath 
tumors (MPNSTs) presented higher UHMK1 
mRNA levels compared to dermal neurofibroma 
(Bieche et al., 2003). 
Bladder cancer 
Silencing of WDR5, a protein shown to be 
upregulated in bladder cancer, reduced the 
H3K4me3 epigenetic marker on its target genes, 
such as UHMK1 and consequently downregulated 
UHMK1 expression in bladder cancer cells (Chen et 
al., 2015). 
Hematological malignancies 
No aberrant expression was observed in patient 
samples with myelodysplastic syndrome (MDS), 
acute myeloid (AML) or lymphoblastic (ALL) 
leukemia. Nonetheless, in MDS patients, increased 
levels of UHMK1 expression positively impacted 
event free and overall survival (Barbutti et al., 2017). 
Schizophrenia 
Puri and colleagues performed a fine mapping by 
genetic association and identified two SNPs within 
the UHMK1 gene (rs10494370, p =.004, and 
rs7513662, p = .043), which showed significant 
association with schizophrenia (Puri et al., 2007). 
The genetic association of these markers was 
confirmed in a second case-control (Puri et al., 
2008). Nevertheless, the association of UHMK1 
with schizophrenia is controversial since the data 
from different cohorts did not support the findings 
(Betcheva et al., 2009; Dumaine et al., 2011). 
Osteoporosis 
The SNP rs16863247 was identified within the 
UHMK1 locus in a genome-wide association study 
(GWAS) carried out to identify genetic variants that 
influence bone mineral density (BMD) in east 
Asians. Thus, UHMK1 was described as a bone 
mineral density susceptibility gene for this ethnical 
group. The authors also showed opposed expression 
levels of UHMK1 during osteoblast and osteoclast 
differentiation and proposed that UHMK1 may play 
a role in bone metabolism by controlling osteoclast 
and osteoblast differentiation (Choi et al., 2016). 
Vascular remodeling and wound 
repair 
Langenickel and coworkers demonstrated the 
importance of UHMK1 expression in controlling 
vascular remodeling and wound repair. These 
processes are characterized by vascular smooth 
muscle cell (VSCM) proliferation and cell 
migration, which can be achieved by inhibiting 
p27Kip1 and Stathmin, two known substrates of 
UHMK1. In a mouse model, deletion of Uhmk1 led 
to accelerated neointima formation and vessel 
occlusion, caused by increased migratory activity of 
VSMCs, as a consequence of diminished 
degradation of Stathmin (Langenickel et al., 2008). 
Corneal fibrosis 
It was shown that FGF2-mediated proliferation of 
corneal endothelial cells (CECs) is partially 
dependent on UHMK1 upregulation and its 
inhibitory effects on CDK inhibitor p27Kip1 (Lee and 
Kay, 2011; Lee et al., 2011). 
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Cerebral visual impairment 
UHMK1 was recently reported among candidate 
genes for cerebral visual impairment (CVI), a major 
cause of low vision in childhood (Bosch et al., 2016). 
To be noted 
It is well accepted that UHMK1 promotes cell cycle 
re-entry by inactivating p27Kip1 following growth 
factor stimulation. Thus it is expected that 
abnormally elevated UHMK1 activity, which is 
supposed to relieve cells from p27Kip-dependent 
growth inhibition, could be involved in some aspects 
of tumor development. Nonetheless, no aberrant 
expression of UHMK1 has been reported amongst 
different cancer samples (Barbutti et al., 2017; 
Bieche et al., 2003), except in a few cases of 
neurological tumors associated with NF1 (Bieche et 
al., 2003). Hence, whether it plays a role in 
tumorigenesis or not remains largely elusive and 
must be further investigated. 
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